Trevena (NASDAQ:TRVN) Coverage Initiated at

Research analysts at assumed coverage on shares of Trevena (NASDAQ:TRVNGet Rating) in a research report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their price target on shares of Trevena to $1.50 in a report on Monday, August 15th.

Trevena Stock Performance

NASDAQ TRVN opened at $3.46 on Wednesday. The company has a quick ratio of 4.51, a current ratio of 4.60 and a debt-to-equity ratio of 0.61. The stock has a market cap of $24.05 million, a price-to-earnings ratio of -0.38 and a beta of 1.86. Trevena has a fifty-two week low of $2.38 and a fifty-two week high of $19.00. The business has a fifty day moving average of $0.87 and a 200-day moving average of $0.50.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Millennium Management LLC purchased a new stake in Trevena in the 2nd quarter valued at about $808,000. Renaissance Technologies LLC increased its position in Trevena by 10.2% during the third quarter. Renaissance Technologies LLC now owns 1,096,100 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 101,900 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Trevena during the first quarter worth approximately $471,000. Virtu Financial LLC raised its stake in Trevena by 72.7% during the third quarter. Virtu Financial LLC now owns 290,480 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 122,242 shares during the period. Finally, Captrust Financial Advisors boosted its holdings in shares of Trevena by 10,526.3% in the 1st quarter. Captrust Financial Advisors now owns 201,900 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 200,000 shares during the last quarter. Hedge funds and other institutional investors own 12.34% of the company’s stock.

About Trevena

(Get Rating)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Further Reading

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with's FREE daily email newsletter.